Acellular soft tissue-derived matrices and methods for preparing same
Compositions including a first soft tissue-derived matrix and a second soft tissue-derived matrix are provided, as well as methods of making such compositions. In some embodiments, the composition comprises delipidated, decellularized adipose tissue-derived matrix and delipidated, decellularized fascial tissue-derived matrix, which may be combined in various proportions. Such adipose-fascia matrix compositions provide improved volume retention when implanted into a patient. The composition may further include exogenous cells or other substances, and/or a carrier. The composition is suitable for use in plastic surgery procedures, including reconstructive or cosmetic surgery procedures, as well as procedures for wound treatment and tissue regeneration. The methods for making the compositions may involve separation of first and second soft tissues from one another, followed by performing one or more treatments on the separated soft tissues, then combining the treated soft tissues and, optionally, performing one or more additional treatments on the combined soft tissues.
1 . A method for increasing, enhancing, or improving volume retention at a region to be treated in a patient, comprising a step of implanting a composition in, on, or proximate to the region to be treated in the patient, thereby forming an implantation site, wherein the composition comprises:
(a) an adipose component which is a delipidized, decellularized adipose tissue-derived matrix; and
(b) a fascia component which is a decellularized fascial tissue-derived matrix;
wherein the adipose component and fascia component are present in the composition in a predetermined ratio of adipose component:fascia component in a range of from about 99:1 to about 1:99 on a weight basis;
whereby the composition provides greater volume retention at an implantation site after passage of a minimum period of time from implantation of the composition in a subject; and
wherein volume retention is greater compared to a composition having a predetermined ratio of 100:0.
2 . The method of claim 1 , further comprising providing a ratio of adipose component:fascia component in the composition which will provide a particular degree of volume retention at the implantation site, wherein the implanted composition comprises the provided ratio of adipose component:fascia component.
3 . The method of claim 2 , wherein the degree of volume retention is provided based on one or more goals selected from: increasing bulk, modifying the shape or contour of a body feature, replacing or supplementing missing or damaged tissue, supplementing existing tissue, providing a stimulus to host tissue, and combinations thereof.
4 . The method of claim 1 , wherein implanting comprises inserting, placing, injecting, and combinations thereof.
5 . The method of claim 1 , wherein the composition further comprises a biocompatible carrier and wherein the step of implanting comprises injecting the composition to implant the composition proximate to the region to be treated.
6 . The method of claim 1 , wherein the step of implanting is performed as part of one or more treatments selected from: augmentation, volume restoration, and deficit management.
7 . The method of claim 1 , wherein the region to be treated comprises a wound, atrophied tissue, diseased tissue, tissue loss, and combinations thereof.
8 . The method of claim 1 , wherein the region to be treated comprises at least a portion of one or more body features selected from: a fat pad, a face, a lip, a joint, a musculoskeletal feature, a cheek, a temple, a nasolabial fold, a wrist, an eyelid, a jaw, and combinations thereof.
9 . A method for cosmetic or reconstructive surgery on a patient having a region to be treated, comprising a step of implanting in, on, or proximate to the region to be treated, thereby forming an implantation site, a composition comprising:
(a) an adipose component which is a delipidized, decellularized adipose tissue-derived matrix; and
(b) a fascia component which is a decellularized fascial tissue-derived matrix;
wherein the adipose component and fascia component are present in the composition in a predetermined ratio of adipose component:fascia component in a range of from about 99:1 to about 1:99 on a weight basis; and
wherein improved volume retention is provided at the implantation site after passage of at least 3 weeks from implantation, as compared to a composition having a predetermined ratio of adipose component:fascia component of 100:0.
10 . The method of claim 9 , further comprising providing a ratio of adipose component:fascia component in the composition which will provide a particular degree of volume retention at the implantation site, wherein the implanted composition comprises the provided ratio of adipose component:fascia component.
11 . The method of claim 10 , wherein the degree of volume retention is provided based on one or more goals selected from: increasing bulk, modifying the shape or contour of a body feature, replacing or supplementing missing or damaged tissue, supplementing existing tissue, providing a stimulus to host tissue, and combinations thereof.
12 . The method of claim 9 , wherein implanting comprises inserting, placing, injecting, and combinations thereof.
13 . The method of claim 9 , wherein the composition further comprises a biocompatible carrier and wherein the step of implanting comprises injecting the composition to implant the composition proximate the region to be treated.
14 . The method of claim 9 , wherein the step of implanting is performed as part of one or more treatments selected from: augmentation, volume restoration, and deficit management.
15 . The method of claim 9 , wherein the region to be treated comprises a wound, atrophied tissue, diseased tissue, tissue loss, and combinations thereof.
16 . The method of claim 9 , wherein the region to be treated comprises at least a portion of one or more body features selected from: a fat pad, a face, a lip, a joint, a musculoskeletal feature, a cheek, a temple, a nasolabial fold, a wrist, an eyelid, a jaw, and combinations thereof.
17 . A method for treatment of a wound site or tissue atrophy site of a patient, comprising a step of implanting, into, on, around, proximate to, or under the wound site or tissue atrophy site, a composition comprising:
(a) an adipose component which is a delipidized, decellularized adipose tissue-derived matrix; and
(b) a fascia component which is a decellularized fascial tissue-derived matrix;
wherein the adipose component and fascia component are present in the composition in a predetermined ratio of adipose component:fascia component in a range of from about 99:1 to about 1:99 on a weight basis; and
whereby tissue healing and reconstruction are facilitated and improved volume retention is provided at the wound site or the tissue atrophy site after passage of at least 3 weeks from implantation, as compared to a composition having a predetermined ratio of adipose component:fascia component of 100:0.
18 . The method of claim 17 , further comprising providing a ratio of adipose component:fascia component in the composition which will provide a particular degree of volume retention at the implantation site, wherein the implanted composition comprises the provided ratio of adipose component:fascia component.
19 . The method of claim 18 , wherein the degree of volume retention is provided based on one or more goals selected from: increasing bulk, modifying the shape or contour of a body feature, replacing or supplementing missing or damaged tissue, supplementing existing tissue, providing a stimulus to host tissue, and combinations thereof.
20 . The method of claim 17 , wherein implanting comprises inserting, placing, injecting, and combinations thereof.
21 . The method of claim 17 , wherein the composition further comprises a biocompatible carrier and wherein the step of implanting comprises injecting the composition to implant the composition proximate the region to be treated.
22 . The method of claim 17 , wherein the step of implanting is performed as part of one or more treatments selected from: augmentation, volume restoration, and deficit management.
23 . The method of claim 17 , wherein the wound site or tissue atrophy site comprises at least a portion of one or more body features selected from: a fat pad, a face, a lip, a joint, a musculoskeletal feature, a check, a temple, a nasolabial fold, a wrist, an eyelid, a jaw, and combinations thereof.